Global life expectancy is back to pre-pandemic levels, but deaths among teens and young adults are rising

New IHME research indicates global life expectancy has recovered to pre-pandemic levels (76.3 for women, 71.5 for men in 2023), with a significant shift from infectious diseases to noncommunicable diseases (NCDs) now comprising two-thirds of global mortality, including rising rates for diabetes and Alzheimer's. Concurrently, an 'emerging crisis' of increasing death rates among adolescents and young adults, particularly from suicide and substance abuse in high-income regions, highlights persistent health inequities and growing healthcare demands. These demographic and epidemiological shifts imply substantial long-term impacts on healthcare sector investment, public policy, and insurance markets, underscoring the need for expanded health priorities amid concerns over international aid funding.

Analysis

Global life expectancy has rebounded to pre-pandemic levels (76.3 years for women, 71.5 years for men in 2023), indicating a broad recovery from COVID-19's direct mortality impact. However, this recovery masks a significant epidemiological shift, with noncommunicable diseases (NCDs) now accounting for approximately two-thirds of global mortality and morbidity, including rising rates for diabetes, chronic kidney disease, and Alzheimer's. This trend, coupled with a rapidly aging global population, signals sustained demand for specialized healthcare services and pharmaceuticals targeting chronic conditions.

A critical "emerging crisis" is the increase in death rates among adolescents and young adults, particularly in high-income North America, driven by suicide, drug overdose, and alcohol. This highlights significant public health challenges and potential long-term societal costs, alongside persistent global health inequities where life expectancy ranges from 83 years in high-income regions to 62 years in sub-Saharan Africa. The research also notes a surging burden from mental health issues like anxiety and depression, indicating a growing need for mental health services and related pharmaceutical interventions.

The IHME emphasizes an "urgent need for policymakers to expand health priorities," especially for younger demographics, and warns that cuts to international aid could unravel progress in low-income regions. This suggests increased regulatory focus and potential fiscal allocation towards preventative care, mental health, and NCD management in developed markets, while emerging markets face heightened risk from reduced global health funding. Approximately half of the world's disease burden is preventable, attributable to modifiable risk factors such as high BMI and high blood sugar, which could drive investment into wellness, nutrition, and public health initiatives.

Key Decisions for Investors

• Investors should increase allocation to healthcare sub-sectors focused on chronic disease management, specialized pharmaceuticals for NCDs like diabetes and Alzheimer's, and medical devices catering to an aging population.
• Consider opportunities in mental health services, digital therapeutics, and related pharmaceutical solutions, given the surging burden of anxiety and depression across demographics.
• Evaluate companies aligned with preventative health, wellness, and nutrition, as approximately half of the global disease burden is preventable, potentially attracting increased public and private investment.
• Monitor policy developments and fiscal allocations related to public health, particularly in high-income regions addressing youth mortality and NCDs, and assess risks in emerging markets due to potential international aid cuts.
• Assess the long-term implications for the life and health insurance sectors, as changing mortality patterns and rising NCDs may necessitate adjustments to actuarial models and product offerings.